Apimeds Pharmaceuticals Files 8-K

Ticker: APUS · Form: 8-K · Filed: Jul 16, 2025 · CIK: 1894525

Apimeds Pharmaceuticals Us, INC. 8-K Filing Summary
FieldDetail
CompanyApimeds Pharmaceuticals Us, INC. (APUS)
Form Type8-K
Filed DateJul 16, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: 8-K, SEC filing, disclosure

TL;DR

Apimeds Pharmaceuticals filed a routine 8-K on July 16th, reporting events from July 15th.

AI Summary

Apimeds Pharmaceuticals US, Inc. filed an 8-K on July 16, 2025, reporting events as of July 15, 2025. The filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The company is incorporated in Delaware and its principal executive offices are located in Matawan, New Jersey.

Why It Matters

This 8-K filing indicates a routine update or disclosure from Apimeds Pharmaceuticals US, Inc. to the SEC, providing information to investors and the public.

Risk Assessment

Risk Level: low — This filing appears to be a standard current report with no immediately apparent significant financial or operational changes disclosed.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Apimeds Pharmaceuticals US, Inc.?

The filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, indicating a disclosure of events as of July 15, 2025.

When was this 8-K report filed with the SEC?

The report was filed on July 16, 2025.

What is the state of incorporation for Apimeds Pharmaceuticals US, Inc.?

The company is incorporated in Delaware.

Where are the principal executive offices of Apimeds Pharmaceuticals US, Inc. located?

The principal executive offices are located at 100 Matawan Rd, Suite 325, Matawan, New Jersey 07747.

What is the IRS Employer Identification Number (EIN) for Apimeds Pharmaceuticals US, Inc.?

The EIN for Apimeds Pharmaceuticals US, Inc. is 85-1099700.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on July 16, 2025 regarding Apimeds Pharmaceuticals US, Inc. (APUS).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing